- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02953405
Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease
November 1, 2016 updated by: Daewoong Pharmaceutical Co. LTD.
Prescription and Persistence of Antithrombotic agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients with MCA(Middle Cerebral Artery) Disease.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- SNUBH
-
Contact:
- Daewoong Clinical
- Phone Number: 82-2-550-8800
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease
Description
Inclusion Criteria:
- 19 years later, men and women
Exclusion Criteria:
- Subject who is judged to be ineligible by investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Prescription status of Antithrombotic Agents
Time Frame: at 12 months after baseline(onset)
|
at 12 months after baseline(onset)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2015
Primary Completion (Anticipated)
November 1, 2018
Study Completion (Anticipated)
November 1, 2018
Study Registration Dates
First Submitted
October 25, 2016
First Submitted That Met QC Criteria
November 1, 2016
First Posted (Estimate)
November 2, 2016
Study Record Updates
Last Update Posted (Estimate)
November 2, 2016
Last Update Submitted That Met QC Criteria
November 1, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Aneurysm
- Aneurysm, Dissecting
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Clopidogrel
Other Study ID Numbers
- DW_CLO001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MCA - Middle Cerebral Artery Dissection
-
University of MinnesotaCompletedIschemic Stroke | MCA InfarctionUnited States
-
University of Roma La SapienzaNot yet recruitingMiddle Cerebral Artery Occlusion With Cerebral Infarction
-
AldagenUnknownStroke | Ischemic Stroke | Stroke in Middle Cerebral Artery (MCA)United States
-
Postgraduate Institute of Medical Education and...CompletedIschemic Stroke | MCA Infarction
-
National University of MalaysiaCytopeutics Sdn. Bhd.UnknownMiddle Cerebral Artery InfarctionMalaysia
-
Assistance Publique - Hôpitaux de ParisTerminatedMalignant Middle Cerebral Artery InfarctionFrance
-
University of MichiganCompletedStroke | Stroke, Chronic | Stroke, Middle Cerebral Artery With InfarctionUnited States
-
Xuanwu Hospital, BeijingRecruitingInfarction, Middle Cerebral Artery | Symptomatic Chronic Middle Cerebral Artery OcclusionChina
-
UCB S.A. - Pharma SectorTerminatedAcute Ischaemic Middle Cerebral Artery StrokeSweden, Argentina, Austria, Belgium, France, Germany, Greece, Hungary, Italy, Norway, Poland, Singapore, Spain, Taiwan, Turkey
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Middle Cerebral Artery With Infarction, Rehabilitation, Upper Limb Recovery, Economic BurdonIndia
Clinical Trials on Clopidogrel
-
Korea University Anam HospitalCompleted
-
Chinese PLA General HospitalUnknownCLOPIDOGREL, POOR METABOLISM of (Disorder)China
-
Ospedale San DonatoCompletedAcute Myocardial InfarctionItaly
-
University of PecsTerminatedStable Angina Pectoris | Ad Hoc Percutaneous Coronary InterventionHungary
-
Hospital Central San Luis Potosi, MexicoUnknownAcute Coronary Syndrome
-
University of North Carolina, Chapel HillCompleted
-
Lady Reading Hospital, PakistanPakistan Chest Society, PakistanRecruitingCOPD | COPD Exacerbation AcutePakistan
-
Deutsches Herzzentrum MuenchenTerminatedCoronary Artery DiseaseGermany
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaCompleted
-
University of PecsHungarian Academy of Sciences; KRKACompletedCoronary Heart Disease | Percutaneous Coronary Intervention